news aktuell GmbH

iMaps Capital Markets expands product portfolio with actively managed certificate for AI trading strategy

Del
With its newly launched Exchange Traded Instrument (ETI), iMaps Capital Markets is pursuing a trading strategy supported by artificial intelligence in order to benefit from developments on the international currency markets.

Liechtenstein, May 19, 2022 – iMaps Capital Markets (iMaps), a brand of the European structured products issuer iMaps ETI AG, in cooperation with Aiternativ Ltd. launched a new exchange-traded investment product: the Aiternativ Dynamic ETI (ISIN: DE000A3GW617). This exchange-traded instrument uses artificial intelligence in the form of a trading algorithm to control the underlying assets in order to generate reliable returns in the forex markets. It has recently been traded on the Stuttgart Stock Exchange and is approved for public distribution in Germany, Liechtenstein, Luxembourg, Spain, Portugal and Austria.

The investment strategy represented by this innovative certificate is based on the total return approach and thus aims to always achieve positive returns with limited risk and to secure the profits already made. Investments are made exclusively in contracts for difference (CFDs), i.e. derivative products, on the foreign exchange market (FOREX). The strategy is based on an automated trading system that identifies, evaluates and, if necessary, trades in short-term volatility breakouts. Aiternative Ltd. developed this system based on strict risk management principles.

In the underlying asset of the actively managed ETI, currencies and contracts for difference can be used for both appreciation (long positions) and depreciation (short positions) assumptions. As a result, it enables extensive flexibility and a return that is independent of the general stock and bond markets.

“I am pleased that we can now add another thematic exchange traded product to our portfolio, which is based on active currency management. Since the currency markets hardly correlate with classic shares and bonds, interesting diversification effects arise,” explains Andreas Woelfl, founder and Chairman of iMaps ETI AG. "The automated investment solution controlled by artificial intelligence, in combination with the total return approach, ensures reliable returns on the foreign exchange markets with a moderate risk profile."

“We are delighted to be listed on the Stuttgart Stock Exchange in partnership with iMaps Capital Markets. This is an important milestone for our company and a great step to build on our long-term vision to become a leading provider of artificial intelligence based trading systems,” said Hugo Malhoa, Head of Business Development at Aiternativ Ltd.

About iMaps ETI AG

iMaps ETI AG is an issuer of Exchange Traded Products (ETP) in the Principality of Liechtenstein with a focus on asset manager certificates in the form of Actively Managed Certificates.

iMaps Capital Markets focuses on providing asset managers with the platform for issuing Exchange Traded Instruments (ETI) as a white label solution in order to map the respective investment strategy. The spectrum represents both ETIs on classic investments such as shares, derivatives and funds, as well as on digital assets as an underlying. As a subgroup of Exchange Traded Products, they are an interesting, rapidly growing and cost-effective alternative to funds. Thanks to the approved securities prospectus of iMaps ETI AG, there is also the possibility of publicly offering ETIs to private investors.

For more information, visit: www.imaps-capital.com 

About Aiternative

Aiternative Ltd. is a Swiss investment advisor to A.R. Suisse Financial GmbH.

Aiternativ's system uses a sophisticated automated trading tool that offers a range of investment opportunities that help investors capitalize on the power of compound interest. An important part of the system works through high-frequency, low-volume (HFLV) transactions. This means that while there are potentially hundreds of opportunities for a successful trade over the lifetime of the investment, only a tiny percentage of the account is used for the trades with the highest probability of success.

With the help of big data, AI and machine learning, historical performance data from numerous data points can be used effectively to better predict future price fluctuations and automatically react to them more effectively.

For more information, visit: www.aiternativ.com.

Contact:
public imaging GmbHGoldbekplatz 3, 22303 HamburgCharlotte Brigitte Looß /
Isabella von Köckritz
Tel.: +49 (0) 40 401999-292 / - 22
E-Mail: imaps@publicimaging.de 

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria18.4.2024 10:15:00 CEST | Press release

Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. PCR test for multiresistant gram-negative (MRGN) bacteria to be developed using novel BioMEMS technology. BioMEMS chips permit simultaneous testing of up to 250 genetic characteristics – in some cases, in less than 15 minutes. Darmstadt, Gerlingen, and Waiblingen, Germany – The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. The two companies will invest a total of 150 million euros by the end of the decade. Within their strategic development and distribution partnership, the partners intend t

Elatec Brings Employee Badge for Apple Wallet to Users17.4.2024 08:45:03 CEST | Press release

Munich, April 17, 2024 – Elatec today announced it is bringing employee badge in Apple Wallet to its customers, enabling an organization’s employees or tenants to unlock access to locations and devices with a simple tap of their iPhone or Apple Watch. Powered by Elatec’s Mobile Credential Manager software, which works hand-in-hand with Elatec’s universal RFID readers, this brings together the world’s most powerful and versatile readers with the best mobile access system available. Employee badge in Apple Wallet helps deliver a convenient and contactless experience for users. Once enabled, employee badge in Apple Wallet allows users to seamlessly and securely add their employee badge to Apple Wallet, and hold their iPhone or Apple Watch near an NFC reader to unlock office doors, turnstiles, elevators and key card-protected amenity spaces — eliminating the need to open an app or present a traditional, plastic access key. With Express Mode, employees do not need to unlock their device to

National Research Center for Applied Cybersecurity ATHENE: Severe Vulnerabilities Discovered in Software to Protect Internet Routing12.4.2024 08:49:14 CEST | Press release

A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key Infrastructure (RPKI). RPKI is an Internet standard meant to protect Internet traffic from being hijacked by hackers. By now, all affected vendors provided patches for their products. The vulnerabilities could have had devastating consequences: Internet hijacks have already been exploited, e.g., for phishing passwords and other sensitive information, tricking certificate authorities into issuing fraudulent Web certificates, stealing cryptocurrency, distributing malware, and poisoning caches of DNS servers.

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment10.4.2024 11:00:00 CEST | Press release

The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom
HiddenA line styled icon from Orion Icon Library.Eye